Today: 11 April 2026
Subscribe
Browse Category

NYSE:MRK 9 January 2026 - 18 January 2026

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson stock heads into earnings after a mild dip — what could move JNJ next

Johnson & Johnson shares closed down 0.4% at $218.66 Friday ahead of the Martin Luther King Jr. Day market holiday. The S&P 500 health care sector fell 0.8%. J&J reports fourth-quarter results Wednesday, Jan. 21, with investors focused on earnings and 2026 guidance. The NYSE will reopen Tuesday after the holiday.
18 January 2026
·······
Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck & Co shares fell 1.9% to $108.83 Friday after a Reuters report highlighted industry concerns over the FDA’s new fast-track drug approval program. Internal FDA documents show some drug reviews have been delayed due to safety and effectiveness worries, including a patient death linked to Sanofi’s Tzield. The S&P 500 healthcare sector dropped 0.8% amid broader market weakness. Only one drug has been approved under the program so far.
17 January 2026
·····
Merck stock slips as FDA fast-track questions build and earnings near

Merck stock slips as FDA fast-track questions build and earnings near

Merck shares fell 1.2% to $109.65 Friday, underperforming the market as investors reacted to renewed scrutiny of the FDA’s expedited drug review program. The FDA delayed reviews of two drugs in the program after safety concerns, including a reported patient death. Merck is developing two drugs under this program and plans to report earnings on Feb. 3. About 7.6 million shares traded by the afternoon.
16 January 2026
··
Dow Jones Today: Dow slips as options expiry hits and investors weigh bank earnings

Dow Jones Today: Dow slips as options expiry hits and investors weigh bank earnings

The Dow Jones Industrial Average fell 70 points, or 0.14%, to 49,372.07 in early Friday trading as losses in healthcare and consumer stocks offset gains in tech. The S&P 500 edged up 0.07%, while the Nasdaq rose 0.26%. PNC Financial jumped 3.9% after reporting a 25% profit increase. Options expiration and muted volatility kept traders cautious near record highs.
16 January 2026
········
Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Merck shares fell 0.2% to $110.75 Thursday after the FDA delayed decisions in its new voucher fast-track program, according to Reuters. The FDA postponed reviews of drugs from Sanofi, Disc Medicine, and Eli Lilly, citing safety concerns. Investors are watching for Merck’s Feb. 3 earnings and updates on its drug pipeline. Healthcare stocks broadly declined, with Eli Lilly down 3.6%.
15 January 2026
···
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

Merck shares closed up 2.54% at $111.01 Wednesday, outperforming a falling U.S. market. Management raised forecasts for new drugs, projecting $70 billion in revenue from growth drivers by the mid-2030s. CEO Rob Davis said Merck has capacity for major deals and is running 80 phase three trials. Investors are watching for Feb. 3 earnings to assess the 2026 outlook.
15 January 2026
···
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
······
Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Merck stock in focus as MRK lifts $70 billion mid-2030s target and points past Keytruda

Merck raised its long-term revenue forecast for new products to $70 billion by the mid-2030s, lifting its cardiometabolic and respiratory outlook to $20 billion and infectious disease to $15 billion. Shares fell 1.2% to $109.19. Johnson & Johnson rose 2.6%, Eli Lilly gained 1.6%, and Pfizer slipped 0.8%. Merck said its pipeline could offset Keytruda’s loss of exclusivity by 2026.
13 January 2026
··
Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck shares fell 1.1% to $109.27 Monday amid speculation over a possible $28–32 billion acquisition of Revolution Medicines, though no deal has been finalized. The SPDR S&P Biotech ETF dropped 2.1%. Analysts estimate Revolution’s RAS inhibitor drugs could generate over $10 billion in sales by 2035. Merck also faces a potential $2 billion annual revenue hit after U.S. vaccine schedule changes affecting Gardasil and RotaTeq.
12 January 2026
··
Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI stock pops 12% premarket after $1.1 billion contracts update — what traders watch next

Tempus AI shares surged about 12% to $74.34 in Monday premarket trading after projecting 2025 revenue of $1.27 billion, up 83% from last year. The company reported total contract value over $1.1 billion and signed data deals with more than 70 clients, including major pharmaceutical firms. Northwestern Medicine announced a new partnership with Tempus to expand genomic cancer testing. Tempus’ figures remain preliminary and unaudited.
12 January 2026
······
Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI stock jumps in premarket after $1.27 billion revenue preview, contract value tops $1.1 billion

Tempus AI shares rose about 11% in premarket trading Monday after the company reported preliminary 2025 revenue of $1.27 billion, up 83% year-on-year, and record contract value exceeding $1.1 billion. The company cited strong growth in both Diagnostics and Data segments, with over 70 new data agreements signed in 2025. Tempus noted the results are unaudited and subject to change.
12 January 2026
·······
Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck shares fell 0.4% to $110.53 Friday as reports surfaced of talks to buy Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped 10.7% on the speculation. The Wall Street Journal and Financial Times said the deal would be among the largest pre-commercial biotech acquisitions. Investors await updates at the JPMorgan Healthcare Conference on Monday.
11 January 2026
···
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck shares fell 0.4% to $110.53 Friday after reports it is in talks to acquire Revolution Medicines for $28–32 billion. Revolution shares jumped in after-hours trading. The Financial Times said negotiations are ongoing, with no final deal yet. Investors are watching Merck’s appearance at the J.P. Morgan Healthcare Conference on Jan. 12.
10 January 2026
··
Cisco (CSCO) stock in focus as Supreme Court takes up Falun Gong lawsuit appeal

Cisco (CSCO) stock in focus as Supreme Court takes up Falun Gong lawsuit appeal

Cisco Systems shares slipped 0.1% to $73.88 after the U.S. Supreme Court agreed to hear its appeal in a lawsuit alleging the company aided China’s surveillance of Falun Gong practitioners. The case centers on whether U.S. law allows “aiding and abetting” claims against corporations for overseas abuses. Cisco denies wrongdoing and welcomed the court’s review. The company will report quarterly earnings on Feb. 11.
10 January 2026
·····
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck shares fell 0.4% to $110.53 after reports it is in talks to acquire Revolution Medicines for up to $32 billion. The company faces new scrutiny over its Gardasil and RotaTeq vaccines after U.S. policy changes, with analysts estimating a $2 billion annual revenue impact. Wolfe Research upgraded Merck, citing progress on a subcutaneous version of Keytruda.
10 January 2026
····
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Revolution Medicines shares surged 10.7% to $118.64 in after-hours trading Friday after the Financial Times reported Merck is in advanced talks to acquire the company for $28 billion to $32 billion. The move follows the FDA granting Breakthrough Therapy designation to Revolution’s zoldonrasib for KRAS G12D-mutated lung cancer. Investors await Revolution’s Jan. 12 conference appearance for updates.
9 January 2026
··
1 2 3 4 5 … 7

Stock Market Today

  • Amdocs (DOX) Shares Dip 22% YTD, DCF Model Shows 52% Undervaluation Opportunity
    April 10, 2026, 10:10 PM EDT. Amdocs (DOX) shares have fallen 22.1% over the past year, raising concerns among investors. Despite the drop, the company retains strong positions in long-term telecom and media contracts. A discounted cash flow (DCF) analysis estimates an intrinsic value of $131.53 per share, over 50% above the current price near $63, signaling potential undervaluation. The model projects free cash flows rising from $645.6 million in 2026 to $1.16 billion in 2035. While market sentiment has soured, Amdocs' valuation score ranks 5 out of 6, indicating attractiveness relative to fundamentals. Investors should monitor the stock's performance amid ongoing sector transformations and large-scale contract projects.

Latest article

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 10:11 PM EDT Bentley Systems (BSY) Stock Drops 7.5% Amid Sector Sell-Off April 10, 2026, 10:11 PM EDT. Bentley Systems (NASDAQ:BSY) shares tumbled 7.5% following a downgrade of ServiceNow (NOW) by UBS, sparking a broader sell-off in infrastructure engineering software stocks. Investors grew concerned over the "seat compression" trend, where AI-driven automation threatens traditional enterprise software's per-seat revenue models. The rise of AI-native rivals and cost-efficient "vibe coding" startups intensified these worries. Despite a relatively calm trading history, today's sharp decline marks significant market reaction. Bentley shares are
MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
Go toTop